Scientific Approach
Translational Medicine
Elpiscience’s translational platform integrates cutting-edge immunobiology, PK/PD analysis, and multi-omics data to optimize drug development for tumor immunotherapy and autoimmune diseases. Our in vitro pharmacodynamics, DMPK & toxicology, and biomarker platforms ensure mechanism-driven research, precise dose selection, and biomarker-driven therapies. Through a science-first, data-driven approach, we accelerate the development of safe and effective breakthrough treatments.
<
>
Proprietary Discovery Platform
-
BiME® - Bispecific Macrophage EngagerBiME® - Bispecific Macrophage EngagerThe BiME® platform activates macrophages to kill tumor cells by blocking the “don’t-eat-me” signal (SIRPα) and delivering an “eat-me” signal via Fc receptor engagement, driving strong phagocytosis and tumor elimination. -
Acebody™ - H - L Interchain Disulfide Bond Engineering BsAb PlatformAcebody™ - H - L Interchain Disulfide Bond Engineering BsAb PlatformAcebody™ is a proprietary H-L interchain disulfide bond engineering platform that enhances IgG-like bispecific antibody stability and pairing efficiency. It enables a simplified production process while preserving the binding and function of the parental mAb. -
ElpiSource™ - Human Antibody Fab LibraryElpiSource™ - Human Antibody Fab LibraryElpiSource is a >10¹⁰ diversity human naïve Fab library displayed on yeast, enabling rapid "target to sequence" discovery in 2-3 months without immunization or humanization. It preserves affinity, generates diverse sequences, and includes both semi-synthetic and fully naïve sub-libraries. -
Elpi-Extend FcElpi-Extend FcElpi-Extend Fc is a proprietary Fc engineering technology that enhances antibody half-life by selectively increasing FcRn binding at acidic pH. This innovation enables less frequent dosing, improved patient compliance, and efficient antibody purification, making it a valuable tool for next-generation therapeutics.
Publications
Learn More